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Rivastigmine is a well-known dual acting acetylcholinesterase and butyrylcholinesterase inhibitor, which
is effective on behavioral and psychiatric symptoms including hallucinations, as well as cognitive
symptoms of dementia. The most common adverse effects of rivastigmine related to cholinergic stim-
ulation in brain and peripheral tissues are gastrointestinal, cardiorespiratory, extrapyramidal, genito-
urinary, musculoskeletal symptoms, sleep disturbances, and skin irritations with the transdermal patch
form in particular. Despite to the previous reports revealing the improving effects of the drug on hal-
lucinations, we presented a-80 year old women with Alzheimer's disease suffering from visual halluci-
nations whose complaints began with rivastigmine treatment. Since the patient had recent memory
disturbance without any behavioral and/or psychiatric symptoms before rivastigmine administration,
and visual hallucinations disappeared with the discontinuation of the drug, visual hallucinations were
attributed to rivastigmine.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rivastigmine is a “pseudo-irreversible” acetyl-and butyrl-
cholinesterase inhibitor with a phenylcarbamate structure which
is an effective treatment option in mild-to-moderate Alzheimer's
disease (AD)1. Since rivastigmine is beneﬁcial in improving pa-
tients' cognitive, behavioral, and daily functioning, it is found to be
effective in mild to moderate dementia associated with Parkin-
son's disease, as well as AD2. In addition to its' oral forms, it is the
ﬁrst cholinesterase inhibitor to be approved as a transdermal patch
(TDP) which is applied once daily. It has three sizes; 5, 10, 15 cm2
releasing 4.6, 9.5, and 13.3 mg rivastigmine/24 hours, respectively,
and available in several countries worldwide3. The most common
adverse effects of rivastigmine, related to cholinergic stimulation
in brain and peripheral tissues are gastrointestinal (nausea, vom-
iting, diarrhea, etc), cardiorespiratory, extrapyramidal (dystonicre that they have no conﬂicts
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es/by-nc-nd/4.0/).reactions, etc.), genitourinary (urinary incontinence), and muscu-
loskeletal symptoms (muscle cramps, weakness), as well as sleep
disturbances4e6. In addition, skin irritations in the localization
area of the patch have been reported for the transdermal
formulation7,8.
Regarding to its' useful effect on behavioral symptoms of de-
mentia, previous studies demonstrated a wider use of rivastigmine
in the treatment of multiple behavioral and psychological symp-
toms of dementia including apathy, anxiety, depression, delusions
and hallucinations, due to its' dual inhibition effect of acetyl-and
butyrl-cholinesterase and brain region selectivity through prefer-
ential inhibition of the G1 isoform of acetylcholinesterase9e11.
Unlike these previous reports of rivastgmine demonstrating the
curative effects on behavioral symptoms, we here presented a
women suffering from visual hallucinations and anxiety due to the
transdermal administration of rivastigmine. According to our
knowledge and literature review, this is the ﬁrst reported case in
which transdermal administration of rivastigmine lead to visual
hallucinations.2. Case-report
An 80-year old woman presented to our outpatient neurology
clinic with visual hallucinations, aggression and loss of appetite.icine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
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systemic and/or neurological diseases except AD and its' medica-
tions. She had the diagnosis of AD since 5 years, and she was under
our dementia outpatient clinic control since 1 year. While she was
using donepezil 10 mg daily without any behavioral and/or psy-
chiatric symptoms, donepezil was tapered gradually and dis-
continued due to the gastrointestinal side-effects as nausea, and
diarrhea which the patient couldn't' t tolerated. So since 1 month,
she was under 4. 6 mg/24 hours rivastigmine patch (© Exelon
patches) treatment. The medical history taken from her daughter
revealed that she was suffering from visual hallucinations since 2
weeks; he was seeing bugs on the wall, and trying to get rid of
them, but the loss of appetite and aggression was gradually
increased within 1 month. However, her main complaint was
recent memory disturbance without any behavioral and/or psy-
chiatric symptoms other than mild depression before rivastigmine
administration. Physical examination of the patient was normal.
Her vital parameters, and routine blood tests including complete
blood count, thyroid function tests, full biochemical screening with
electrolytes, liver and kidney function tests were normal. Neuro-
logical examination of the patient revealed a recent memory loss
with mini-mental state exam score of 20/30 points. Her psycho-
logical assessment revealed aggressiveness, anxiety, and visual
hallucinations.
Regarding to the psychiatric symptoms of the patient, riva-
stigmine patch was stopped, and switched to donepezil 5 mg/daily.
One week after the discontinuation of rivastigmine, the daughter of
the patient stated that the visual hallucinations were diminished,
and her aggression was reduced without any antipsychotic
treatment.
3. Discussion
Hallucinations in AD, are the symptoms of moderate to severe
AD, which are the indicator of cortical cholinergic deﬁcits. Under-
lying cause of the hallucinations in AD is the cholinergic neuronal
loss and a subsequent decline in the acetylcholine levels of brain
regions which are responsible for the behavioral and emotional
responses, in particular12. As a moderate to severe complaint of AD,
hallucinations may present in 20-40 % of AD patients, and visual
hallucinations are the most common form13.
We here presented an AD patient with visual hallucinations
which began with rivastigmine treatment and disappeared within
the discontinuation of the drug. However, the introduction of
rivastigmine led to improvements in cognitive and functional
abilities, as well as the resolution of behavioural problems and vi-
sual hallucinations2.
As we know from the previous studies and reports, rivastigmine
is a well-known dual inhibitor of acetylcholinesterase and butyr-
ylcholinesterase that shows brain region selectivity. The behavior
domains that most consistently showed improvement with riva-
stigmine therapy are apathy/indifference, anxiety, delusions (psy-
chosis), and hallucinations2,9,14. Suggesting the positive role of
cholinesterase inhibitors on psychiatric symptoms, previous re-
ports demonstrated the improvement of visual hallucinations in
wide range of dementias including Parkinson's disease dementia,
Alzheimer's disease, vascular dementia, and frontotemporal
dementia2,12,15.
In conclusion, despite the well-known positive effects of riva-
stigmine over visual hallucinations, and anxiety as well as other
behavioral symptoms of dementia, we would like to share this
unique patient as a case report who experienced visual hallucina-
tions under rivastigmine treatment. The existence of hallucinations
despite the low dose of rivastigmine in our patient may beexplained by the variable pharmacokinetics of rivastigmine from
person to person, which may be responsible for the hallucinatory
side-effect similar to an overodose of rivastigmine.
Since the patient had no behavioral symptoms before riva-
stigmine treatment, and the visual hallucinations disappeared after
the discontinuation of the drug, we attributed these hallucinations
to rivastigmine itself as a side effect, and shared as a unique case-
report.
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